Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells
John Wharton(Pfizer (United Kingdom)), Martin R. Wilkins(Hammersmith Hospital), Gigi M. O. Møller(Pfizer (United Kingdom)), Julian Strange(NIHR Bristol Cardiovascular Biomedical Research Unit), Xiaohui Ren(Pfizer (United Kingdom)), Angela P. Franklyn(Pfizer (United Kingdom)), Ellena Growcott(Pfizer (United Kingdom)), Stephen C. Phillips(Pfizer (United Kingdom))
Cited by 367
Related Papers
Definitions and Diagnosis of Pulmonary Hypertension
|Journal of the American College of Cardiology|2013|1.8k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k
Mechanisms of disease: pulmonary arterial hypertension
|Nature Reviews Cardiology|2011|784
Basic Science of Pulmonary Arterial Hypertension for Clinicians
|Circulation|2010|488
Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension
|Circulation|2001|487